AbbVie Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $28.22B | $25.64B | $22.86B | $19.96B | $18.79B | $18.38B | $17.44B |
| Immunology | — | — | — | — | — | — | — |
| Neuroscience | — | — | — | — | — | — | — |
| Oncology | — | — | — | — | — | — | — |
| Aesthetics | — | — | — | — | — | — | — |
| Eye Care | — | — | — | — | — | — | — |
| Other | — | — | — | — | — | — | — |
| Cost of Revenue | $7.04B | $5.83B | $4.50B | $4.43B | $4.58B | $4.51B | $4.64B |
| Gross Profit | $21.17B | $19.81B | $18.36B | $15.53B | $14.21B | $13.87B | $12.81B |
| Gross Margin | 75.0% | 77.3% | 80.3% | 77.8% | 75.6% | 75.5% | 73.4% |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | — |
| SG&A Expense | $6.30B | $5.88B | $6.39B | $7.72B | $5.35B | $4.99B | $5.89B |
| Operating Income | $9.55B | $9.34B | $7.54B | $3.41B | $5.66B | $5.82B | $3.62B |
| Operating Margin | 33.8% | 36.4% | 33.0% | 17.1% | 30.1% | 31.6% | 20.8% |
| Interest Expense | $1.15B | $1.05B | $719.0M | $429.0M | $299.0M | $104.0M | — |
| Pretax Income | $7.73B | $7.88B | $6.65B | $2.37B | $5.33B | $5.73B | $3.67B |
| Income Tax Expense | $2.42B | $1.93B | $1.50B | $595.0M | $1.20B | $450.0M | $235.0M |
| Net Income | $5.31B | $5.95B | $5.14B | $1.77B | $4.13B | $5.28B | $3.43B |
| Net Margin | 18.8% | 23.2% | 22.5% | 8.9% | 22.0% | 28.7% | 19.7% |
| EPS (Basic) | $3.31 | $3.65 | $3.15 | $1.11 | $2.58 | $3.35 | $2.18 |
| EPS (Diluted) | $3.30 | $3.63 | $3.13 | $1.10 | $2.56 | $3.35 | $2.18 |
| Shares Outstanding (Basic) | 1.60B | 1.62B | 1.63B | 1.60B | 1.59B | 1.58B | 1.58B |
| Shares Outstanding (Diluted) | 1.60B | 1.63B | 1.64B | 1.61B | 1.60B | 1.58B | 1.58B |
| Dividends Per Share | $2.63 | $2.35 | $2.10 | $1.75 | $2.00 | — | — |